Revive Therapeutics Ltd. (TSX-V: RVV) (OTCQB: RVVTF) (FSE: 31R) is focused on the research, development and commercialization of novel medical products and cannabinoid-based pharmaceuticals by identifying and investigating potential therapies targeting the endocannabinoid system, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities.